Table 2.
RU and RR cell populations are detectable in primary patient breast tumors
| Patient number | Infection efficiency (RFP+) | RR cells (GFP+/RFP+), % | Nuclear Sox2 (IHC) | Estrogen receptor status |
|---|---|---|---|---|
| 1 | 64.2% | 13.9% | 2+ | + |
| 2 | 48.7% | 11.0% | 2+ | + |
| 3 | 63.1% | 16.1% | 1+ | + |
| 4 | 57.8% | 0.6% | N/A | - |
| 5 | 43.0% | 10.8% | N/A | + |
| 6 | 49.7% | 0.3% | 3+ | - |
| 7 | 81.3% | 12.5% | N/A | + |
| 8 | 77.3% | 21.4% | 1+ | + |
| 9 | 36.3% | 0.4% | N/A | - |
| 10 | 61.0% | 11.5% | N/A | + |
| 11 | - * | 5.7% | 0 | + |
| 12 | - * | 5.8% | 3+ | + |
| 13 | - * | 17.0% | N/A | + |
| 14 | - * | 21.6% | N/A | + |
| 15 | - * | 23.8% | 3+ | + |
| 16 | - * | 19.6% | 2+ | + |
| 17 | -* | 5.4% | N/A | N/A |
| 18 | -* | 10.5% | N/A | N/A |
| 19 | -* | 5.8% | N/A | N/A |
Flow cytometry analyses of red fluorescent protein (RFP) and green fluorescent protein (GFP) in mCMV-GFP-EF1-Puro infected primary breast tumor cells to set the gate thresholds and the SRR2-mCMV-GFP-EF1-RFP infected primary breast tumor cells showing % RFP+ cells (lentivirus infection efficiency) and % RFP+ GFP+ cells (% of patient reporter responsive (RR) cells). Table summarizes data from 19 primary breast tumor samples. The asterisks denote samples where the primary breast tumor cells % RFP+ could not be accurately assessed due to technical issues but is estimated to be approximately 60%. IHC denotes immunohistochemistry; N/A, not analyzed.